TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06702007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHaRT-A
Description: Adaptation of the Harm Reduction Treatment for Alcohol (HaRT-A) into a digital telehealth platform facilitating harm reduction treatment via patient-provider video sessions (eHaRT-A). eHaRT-A will include the three treatment components from the efficacious HaRT-A. eHaRT-A will be delivered during one-on-one sessions through video conferencing with interactive features (i.e., personalized feedback tracked over time and screen sharing).
Study: NCT06699810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: After insulin discontinuation participants continue wearing their CGMs, for a total of 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Participants will receive standard-of-care insulin treatment. Insulin dosing will be adjusted based on CGM glucose readings.
Study: NCT06703892

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GF-CART01
Description: CAR positive viable T cells-Mid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GF-CART01
Description: CAR positive viable T cells-High
Study: NCT05763550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 40mg BID
Description: HSK16149 40mg, orally twice a day, treatment period; 4-weeks fixed dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: pregabalin, orally twice a day, treatment period; 150 mg (75 mg twice daily) for 1 week；300 mg (150 mg twice daily) daily for 3 week
Study: NCT06163170

Intervention type: DRUG
Intervention: Nivolumab +/- ipilimumab
Description: Participants treated with nivolumab +/- ipilimumab for unresectable/metastatic melanoma

Intervention type: DRUG
Intervention: Nivolumab
Description: Participants treated with nivolumab as adjuvant therapy for resected stage IIB-IV melanoma
Study: NCT06703892

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GF-CART01
Description: CAR positive viable T cells-Low
Study: NCT06703398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC101 TIL
Description: Patients with advanced melanoma (excluding uveal melanoma) who have failed to PD-1 antibodies (if BRAF mutation is present, BRAF and MEK inhibitors have failed; if NRAS mutation is present, tunlametinib have failed) and are ineligible for resection
Study: NCT04792164

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultra sound guided nerve block
Description: Ultra sound guided nerve block by lidocaine before open inguinal hernia repair.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Usual infiltration
Description: Usual infiltration by lidocaine before open inguinal hernia repair.
Study: NCT06703398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin
Description: monotherapy or combination of dacarbazine, temozolomide, paclitaxel, platinum or cisplatun, and the chemotherapy's dosage could refer to the drug label or the relevant treatment guideline, the final decision is up to investigator
Study: NCT06695845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Administered by intravenous (IV) infusion
Study: NCT06706674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone high dose
Description: Lumateperone administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone low dose
Description: Lumateperone administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo administered orally once daily
Study: NCT06712641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin + narrow spectrum betalactam
Description: Empirical therapy for suspected community-acquired sepsis with gentamicin + narrow spectrum betalactam (either one of penicillin, ampicillin, or cloxacillin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefotaxime
Description: Empirical therapy for suspected community-acquired sepsis with cefotaxime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin-tazobactam
Description: Empirical therapy for suspected community-acquired sepsis with piperacillin-tazobactam
Study: NCT06706999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PREVAIL model of care
Description: Components 1, 2, and 3 are essential components that all participants will receive. Components 4 and 5 are based on the results of either the DAPS tool or the PT consultation call.~1. Screening tool (DAPS) completed at baseline to determine current level of limitation with valued life activities.~2. Recommendation to rheumatology clinician based on screening results to provide exercise resource and/or recommend a PT consult call during routine visit.~3. Exercise resource (PREVAIL website) provided to all participants by their rheumatology clinician at their routine visit.~4. Brief consultation call with a study physical therapist to determine level of priority for PT referral. Only applicable for those with/at risk for limitation with valued life activities.~5. Referral to PT. Only applicable if determined by study physical therapist to meet priority requirements.
Study: NCT06706752

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Shengbai Oral Formula
Description: Shengbai Oral Formula contains 11 herbs: Folium Epimedii, Fructus Lycii, Radix Astragali, Caulis Spatholobi, Radix Rubiae, Rhizoma Phragmitis, Fructus Psoraleae, Radix Angelicae Sinensis, Radix Ophiopogonis,, Radix et Rhizoma Glycyrrhizae, Radix Aconiti Lateralis Preparata (Processed). It is taken by mouth three times per day for 14 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Placebo
Description: Inactive placebo will be taken by mouth three times per day for 14 days.
Study: NCT06709456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided pleural drainage
Description: Ultrasonography-guided pleural drainage with insertion of a small-bore intrapleural catheter. Contralateral and repeated drainage conducted as specified during ICU stay until day 90.
Study: NCT06707233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SIRT
Description: The patients will receive 1-2 sessions of SIRT.
Study: NCT06144489

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tart Cherry
Description: Tart cherry supplementation in two doses

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tart Cherry
Description: Tart cherry supplementation in two doses
Study: NCT06714006

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PYC-003
Description: A peptide-phosphorodiamidate morpholino oligonucleotide conjugate administered as a single intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PYC-003
Description: A peptide-phosphorodiamidate morpholino oligonucleotide conjugate administered as a single intravenous infusion
Study: NCT06714461

Intervention type: DRUG
Intervention: Leflunomide
Description: This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.
Study: NCT06714448

Intervention type: DRUG
Intervention: Sodium valporate
Description: This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.
Study: NCT06714357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: Administered at the dosage of 180 mg/m2 over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Administered at the dosage of 180 mg/m2 over 60 minutes
Study: NCT06144489

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group
Study: NCT05807139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone and its matched placebo will be encapsulated into hard gelatin capsules, in same color, size and taste, to allow blinding.~Participants will receive 2x50 mg/day, 2x100 mg, and 2x200 mg/day in three sessions (Stages); these Visits always occur in ascending order of dosage. In the remaining session, participants receive the placebo.~Spironolactone is approved by the FDA, commercially available, and used in clinical practice for the treatment of hypertension, NYHA Class III-IV heart failure, edema in cirrhotic patients, and primary hyperaldosteronism. Comprehensive information about spironolactone, including its pharmacological properties, are provided in the Prescribing Information.
Study: NCT06470750

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT06714357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: panitumumab
Description: Administered as 60 minutes, or 90 minutes for doses over 1000 mg, intravenous infusion at the dosage of 6 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Administered as 60 minutes, or 90 minutes for doses over 1000 mg, intravenous infusion at the dosage of 6 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid (VPA)
Description: VPA will be administered in each patient with a titration strategy to improve the compliance for the treatment, looking for a target serum level between 50 and 100 μg/mL that represents the recommended values for the treatment of epilepsy and also a useful concentration to produce the desired synergistic effect with chemotherapy based on preclinical studies.~Administrated at the dosage of 500 mg/three times a day (after 7 days of gradual dose escalation).
Study: NCT06713707

Intervention type: OTHER
Intervention: Manuel dexterity
Description: Individuals who meet the inclusion criteria will be evaluated for manual dexterity using 9-HPT, and JTHFT.

Intervention type: OTHER
Intervention: Manual Dexterity (only MMDT)
Description: Individuals who meet the inclusion criteria will be evaluated for manual dexterity using MMDT on a predetermined day.

Intervention type: OTHER
Intervention: Manual Dexterity (only MMDT)
Description: Individuals who meet the inclusion criteria will be evaluated for manual dexterity using MMDT on a predetermined day.
Study: NCT06718491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Managing Physical Reactions to Overwhelming Emotions (IMPROVE)
Description: Participants may be randomized to IMPROVE. IMPROVE is a three session virtual intervention delivered by research clinicians and augmented by a mobile application. The treatment is designed to target and reduce distress contributing to heavy alcohol use during medication for opioid use disorder treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Training (HET)
Description: Participants may be randomized to HET. HET is an active control intervention that is equally intensive as IMPROVE It includes three virtual sessions and a mobile application. HET is designed to target healthy lifestyle behaviors such as diet and sleep.
Study: NCT06688058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V540D
Description: Experimental vaccine and adjuvant administered via intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GARDASIL®9
Description: Suspension administered via IM injection
Study: NCT06713590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Axatilimab will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Axatilimab will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Axatilimab will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Axatilimab will be administered at protocol defined dose.
Study: NCT06715371

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiography (TTE) and Transesophageal Echocardiography (TEE)
Description: Transthoracic echocardiography (TTE) is a non-invasive imaging technique performed by placing an ultrasound transducer on the chest to obtain detailed heart images. TTE is conducted preoperatively on awake patients within two weeks prior to cardiac surgery, following ASE chamber quantification guidelines.~Transesophageal echocardiography (TEE) is an invasive imaging technique where an ultrasound transducer is placed in the esophagus, providing closer and clearer images of the heart. TEE is performed intraoperatively under general anesthesia as part of routine care.
Study: NCT06717295

Intervention type: DIAGNOSTIC_TEST
Intervention: DiNanoQ: A multi-cancer early detection (MCED) blood test
Description: Procedure: Participants will undergo a single blood draw at baseline.~Sample Analysis:~Platelet Isolation: Platelets will be extracted from the collected blood samples.~RNA Analysis: RNA from the isolated platelets will be extracted and analyzed using AI-based transcriptomic profiling to identify biomarkers associated with cancer.

Intervention type: DIAGNOSTIC_TEST
Intervention: DiNanoQ: A multi-cancer early detection (MCED) blood test
Description: Procedure: Participants will undergo a single blood draw at baseline.~Sample Analysis:~Platelet Isolation: Platelets will be extracted from the collected blood samples.~RNA Analysis: RNA from the isolated platelets will be extracted and analyzed using AI-based transcriptomic profiling to identify biomarkers associated with cancer.

Intervention type: DIAGNOSTIC_TEST
Intervention: DiNanoQ: A multi-cancer early detection (MCED) blood test
Description: Procedure: Participants will undergo a single blood draw at baseline.~Sample Analysis:~Platelet Isolation: Platelets will be extracted from the collected blood samples.~RNA Analysis: RNA from the isolated platelets will be extracted and analyzed using AI-based transcriptomic profiling to identify biomarkers associated with cancer.

Intervention type: OTHER
Intervention: DiNanoTrack: Therapeutic Response Monitoring Blood Test
Description: Procedures:~Blood Sample Collection: Participants will have blood samples drawn at three time points:~Baseline: Before therapy initiation. 6 Weeks Post-Therapy Initiation: To monitor early treatment response. 6 Months Post-Therapy Initiation: To assess longer-term therapeutic outcomes.~Sample Analysis:~Platelet and Immune Cell Isolation:~Platelets: Extracted from each blood sample to continue monitoring RNA profiles.~Immune Cells: Separated from the blood samples to analyse immune response to therapy.~RNA Analysis:~Platelet RNA: Analysed to observe changes in transcriptomic profiles over time using AI-based tools.~Immune Cell RNA: Examined to assess transcriptomic changes associated with therapeutic responses.~Data Correlation:~Therapeutic Response Assessment: RNA profiles from platelets and immune cells will be correlated with clinical outcomes to identify biomarkers predictive of treatment efficacy, progression-free survival, relapse, and drug resistance.
Study: NCT06721091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNA-318
Description: Part 1 will consist of administration of VNA-318 at the doses of 5 mg to 180 mg in 5 successive cohorts.~Part 2 will consist of administration of VNA-318 in 3 successive cohorts. The doses will be selected based on safety and tolerability assessments, aw well as the observed PK and PD data from the SAD part.~For each SAD and MAD cohort, a sentinel group of 2 subjects will initially be randomized to receive VNA-318 or placebo (1:1 ratio)~Once PK suggests that the therapeutic dose has been reached in the SAD part, the SAD and MAD parts of the study could be run in parallel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNA-318
Description: Part 1 will consist of administration of VNA-318 at the doses of 5 mg to 180 mg in 5 successive cohorts.~Part 2 will consist of administration of VNA-318 in 3 successive cohorts. The doses will be selected based on safety and tolerability assessments, aw well as the observed PK and PD data from the SAD part.~For each SAD and MAD cohort, a sentinel group of 2 subjects will initially be randomized to receive VNA-318 or placebo (1:1 ratio)~Once PK suggests that the therapeutic dose has been reached in the SAD part, the SAD and MAD parts of the study could be run in parallel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1 (SAD) will consist of administration of matching placebo at the doses of 5 mg to 180 mg in 5 successive cohorts.~Part 2 will consist of administration of matching placebo in 3 successive cohorts. The doses will be selected based on safety and tolerability assessments, aw well as the observed PK and PD data from the SAD part.~For each SAD and MAD cohort, a sentinel group of 2 subjects will initially be randomized to receive VNA-318 or placebo (1:1 ratio)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1 (SAD) will consist of administration of matching placebo at the doses of 5 mg to 180 mg in 5 successive cohorts.~Part 2 will consist of administration of matching placebo in 3 successive cohorts. The doses will be selected based on safety and tolerability assessments, aw well as the observed PK and PD data from the SAD part.~For each SAD and MAD cohort, a sentinel group of 2 subjects will initially be randomized to receive VNA-318 or placebo (1:1 ratio)
Study: NCT06722430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icalcaprant
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole (ITZ)
Description: Oral capsule
Study: NCT06722417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icalcaprant
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icalcaprant
Description: Oral capsules
Study: NCT06703658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5004(Part A)
Description: Single dose of AZD5004 oral on Day1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo(Part A)
Description: Single dose of placebo oral on Day1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5004(Part B)
Description: AZD5004 will be administered as an oral tablet once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo(Part B)
Description: Placebo will be administered as an oral tablet once daily.
Study: NCT06718361

Intervention type: OTHER
Intervention: Oxygen levels measurement (%)
Description: Measuring levels of oxygen in the environment around the patient in %.

Intervention type: OTHER
Intervention: Oxygen levels measurement (%)
Description: Measuring levels of oxygen in the environment around the patient in %.

Intervention type: OTHER
Intervention: Oxygen levels measurement (%)
Description: Measuring levels of oxygen in the environment around the patient in %.

Intervention type: OTHER
Intervention: Oxygen levels measurement (%)
Description: Measuring levels of oxygen in the environment around the patient in %.

Intervention type: OTHER
Intervention: Oxygen levels measurement (%)
Description: Measuring levels of oxygen in the environment around the patient in %.
Study: NCT06717347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilovertamab vedotin
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab Biosimilar
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab Biosimilar
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: IV infusion
Study: NCT06726343

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fetal Monitoring Device
Description: Fetal monitoring device is a multi-parameter maternal fetal monitor that is intended to monitor, store, display, transmit, and generate alarms for non-invasive and invasive clinical parameters of pregnant women and fetuses (singleton and twin), during the antepartum, intrapartum, and postpartum period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fetal Monitoring Device
Description: Fetal monitoring device is a multi-parameter maternal fetal monitor that is intended to monitor, store, display, transmit, and generate alarms for non-invasive and invasive clinical parameters of pregnant women and fetuses (singleton and twin), during the antepartum, intrapartum, and postpartum period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fetal Monitoring Device
Description: Fetal monitoring device is a multi-parameter maternal fetal monitor that is intended to monitor, store, display, transmit, and generate alarms for non-invasive and invasive clinical parameters of pregnant women and fetuses (singleton and twin), during the antepartum, intrapartum, and postpartum period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Investigational Fetal Monitoring Device
Description: Fetal monitoring device is a multi-parameter maternal fetal monitor that is intended to monitor, store, display, transmit, and generate alarms for non-invasive and invasive clinical parameters of pregnant women and fetuses (singleton and twin), during the antepartum, intrapartum, and postpartum period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Investigational Fetal Monitoring Device
Description: Fetal monitoring device is a multi-parameter maternal fetal monitor that is intended to monitor, store, display, transmit, and generate alarms for non-invasive and invasive clinical parameters of pregnant women and fetuses (singleton and twin), during the antepartum, intrapartum, and postpartum period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Investigational Fetal Monitoring Device
Description: Fetal monitoring device is a multi-parameter maternal fetal monitor that is intended to monitor, store, display, transmit, and generate alarms for non-invasive and invasive clinical parameters of pregnant women and fetuses (singleton and twin), during the antepartum, intrapartum, and postpartum period.